Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. Reply

N Engl J Med. 2022 Feb 24;386(8):804. doi: 10.1056/NEJMc2120127.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Fibrillation* / drug therapy
  • Atrial Fibrillation* / surgery
  • Humans
  • Pyridines
  • Thiazoles / therapeutic use
  • Transcatheter Aortic Valve Replacement*
  • Vitamin K / antagonists & inhibitors

Substances

  • Anticoagulants
  • Pyridines
  • Thiazoles
  • Vitamin K
  • edoxaban